Compare IMAX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMAX | MESO |
|---|---|---|
| Founded | 1967 | 2004 |
| Country | Canada | Australia |
| Employees | N/A | 81 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1997 | N/A |
| Metric | IMAX | MESO |
|---|---|---|
| Price | $35.67 | $16.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $44.50 | N/A |
| AVG Volume (30 Days) | ★ 991.7K | 276.9K |
| Earning Date | 04-30-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $410,212,000.00 | N/A |
| Revenue This Year | $9.79 | $629.74 |
| Revenue Next Year | $7.51 | $30.65 |
| P/E Ratio | $55.48 | ★ N/A |
| Revenue Growth | ★ 16.47 | N/A |
| 52 Week Low | $22.50 | $9.88 |
| 52 Week High | $43.16 | $21.50 |
| Indicator | IMAX | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 61.29 |
| Support Level | $33.34 | $14.44 |
| Resistance Level | $37.52 | $17.89 |
| Average True Range (ATR) | 1.44 | 0.53 |
| MACD | -0.30 | 0.29 |
| Stochastic Oscillator | 18.98 | 93.92 |
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.